Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CPT1A | P50416 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 14/20 | 0.41 |
| ▸ | CNR1 | P21554 | 10/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001736 | 0.88 | CPT1A (0.47) | SMN1; SMN2LMNAALDH1A1CPT1ACNR2 | |
| SCHEMBL2003078 | 0.86 | CPT1A (0.42) | ALDH1A1CPT1ACNR2CNR1 | |
| SCHEMBL2007219 | 0.85 | CPT1A (0.45) | SMN1; SMN2LMNAALDH1A1CPT1ACNR2 | |
| SCHEMBL2001377 | 0.85 | CPT1A (0.44) | CPT1ACNR2 | |
| SCHEMBL2002327 | 0.82 | CPT1A (0.42) | CPT1ACNR2CNR1 | |
| SCHEMBL2006404 | 0.82 | CPT1A (0.42) | LMNAALDH1A1CPT1A | |
| SCHEMBL2002383 | 0.81 | CPT1A (0.43) | SMN1; SMN2LMNAALDH1A1CPT1AMAPT | |
| SCHEMBL1999582 | 0.81 | CPT1A (0.41) | SMN1; SMN2ALDH1A1CPT1ACNR1MAPT | |
| SCHEMBL2003873 | 0.80 | CPT1A (0.41) | CPT1ACNR2MAPT | |
| SCHEMBL13670217 | 0.78 | CPT1A (0.43) | LMNAALDH1A1CPT1ACNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | SMN1; SMN2 4017/4885LMNA 3572/4885ALDH1A1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.